FDA Says CLIA Labs Can Use Cepheid's Xpert GBS Test in POC Setting | GenomeWeb
NEW YORK (GenomeWeb News) – The US Food and Drug Administration has said CLIA labs can use Cepheid’s Xpert Group B Streptococcus test, Cepheid said today.
 
Last month the agency cleared the test as an in vitro diagnostic. The recent move, which categorizes the Xpert test as "moderate complexity," means the test can be used by 27,000 additional labs.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.